期刊
BIOMARKER RESEARCH
卷 10, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40364-022-00352-w
关键词
Chimeric antigen receptor T-cells; CD7; Early T-cell precursor lymphoblastic leukemia/lymphoma; Relapsed / refractory
资金
- National Natural Science Foundation of China [81873443, 81900175]
- Major Natural Science Research Projects in institutions of higher education of Jiangsu Province [19KJA210002]
- Key Science Research Project of Jiangsu Commission of Health [K2019022]
- Natural Science Foundation of Jiangsu Province [BK20190181, BK20201169, BK20170360]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Translational Research Grant of NCRCH [2020ZKZC04]
This case demonstrates that CD7-CART is an effective and safe salvage therapy in patients with relapsed/refractory ETP-ALL/LBL and high tumor burden.
Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies. Here we present the anti-CD7 CART therapy in a 11-year-old male with TP53 mutated relapsed/refractory ETP-ALL/LBL. The patient suffered second relapse after haploidentical hematopoietic stem cell transplantation, showing resistance to 4 lines salvage therapies including venetoclax. Nanobody derived CD7-CART cells were manufactured by co-transducing CAR-T cells with a CD7 protein expression blocker. 70.5% of blasts (CD7 expression: 92.6%) and extensive extramedullary disease (mediastinal mass, enlarged lymph nodes and spleen) were observed prior to CD7-CART-cell therapy. A total of 5 x 10(6)/kg donor-derived CD7-CART-cells were infused. Hematological and extramedullary remission were both achieved, with persistence of CD7-CART-cells be detected until the last followup at 96th days after the infusion. Reversible adverse effects including grade 3 cytokine release syndrome and macrophage activation syndrome were observed. This case demonstrated that CD7-CART was a potent and safe salvage therapy in relapsed/refractory ETP-ALL/LBL patient with high tumor burden.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据